GENE ONLINE|News &
Opinion
Blog

INTERACT Study
Trials & Approvals INTERACT Study
Neurocrine, Takeda Look to Build on Positives Post Luvadaxistat’s Schizophrenia Trial Failure
2021-03-03
BIO Digital 2020 Highlights: Challenges in Bringing New Cell and Gene Therapies to Market
2020-06-23
LATEST
Wendy Short Bartie Repositions Bristol Myers Squibb Corporate Affairs to Integrate Patient Advocacy and Healthcare Access
2026-09-14
Wendy Short Bartie Restructures Bristol Myers Squibb Corporate Affairs to Link Reputation with Business Performance
2026-09-14
Wendy Short Bartie Integrates Patient Advocacy and Public Trust into Bristol Myers Squibb Business Strategy
2026-09-14
Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch of Next-Generation ADCs
2026-09-14
Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise
2026-09-14
GO PRIME
FDA Approves Bayer’s Sevabertinib as First-Line Treatment for Adults Living with HER2-Mutant Lung Cancer
2026-09-14
Takeda R&D President Andy Plump and GV Managing Partner Krishna Yeshwant Announce Retirements
2026-09-12
READ MORE
EVENT
2026-09-16
BIOHK (16–19, Hong Kong) (Hong Kong biotech & investment)
Hong Kong
2026-10-07
BioJapan / HealthTECH JAPAN (Biotech, Medtech, Regenerative)
Yokohama, Japan
2026-10-07
Hospital Expo Tokyo (Devices & Hospital IT)
Tokyo, Japan
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
2026-10-23
ESMO Congress 2026 (Oncology Breakthroughs)
Madrid, Spain
2026-10-27
ESGCT 2026 (Gene & Cell Therapy)
Hamburg, Germany
SEE MORE
Scroll to Top